Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00042003 · ClinicalTrials.gov registry record · Phase 2
Phase II Trial of Decitabine in Patients With Chronic Myelogenous Leukemia Blast Phase Who Are Refractory to Imatinib Mesylate (Gleevec)
A Phase 2 study, sponsored by Astex Pharmaceuticals.
- Completed
- Registry status
- Phase 2
- Development phase
- 40
- Enrollment target
NCT00042003 is a Phase 2 study that has completed, run by Astex Pharmaceuticals. The registered enrollment target is 40 participants.
The verdict
NCT00042003, a Phase 2 study, has completed, sponsored by Astex Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 40 participants
- Enrollment target
Study Summary
To determine the safety and efficacy of decitabine in patients with Philadelphia chromosome-positive chronic myelogenous leukemia blastic phase that were previously treated with imatinib mesylate (STI 571) and became resistant/refractory or were found to be intolerant to the drug.
Interventions
- DRUG decitabine (5-aza-2'deoxycytidine)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 40 participants |
| Start Date | 2002-07 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00042003
The ClinicalTrials.gov registry entry for NCT00042003 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 40 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Astex Pharmaceuticals, which has 38 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which decitabine (5-aza-2'deoxycytidine) is the first listed.
NCT00042003 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00042003 about?
NCT00042003 is a clinical study titled "Phase II Trial of Decitabine in Patients With Chronic Myelogenous Leukemia Blast Phase Who Are Refractory to Imatinib Mesylate (Gleevec)". To determine the safety and efficacy of decitabine in patients with Philadelphia chromosome-positive chronic myelogenous leukemia blastic phase that were previously treated with imatinib mesylate (STI 571) and became resistant/refractory or were found to be intolerant to the drug.
What is the current status of trial NCT00042003?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 40 participants. The study started on 2002-07.
What interventions are being tested in trial NCT00042003?
The interventions under investigation include: decitabine (5-aza-2'deoxycytidine) (DRUG).
Who is sponsoring clinical trial NCT00042003?
This trial is sponsored by Astex Pharmaceuticals, which has 38 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.